{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:13:02Z","timestamp":1789841582788,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T18:03:28Z","timestamp":1488996208000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour\u00a0patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-5033","authenticated-orcid":false,"given":"Sheima","family":"Farag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe","family":"Heeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nederlof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Grunhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2017.02.007_bib1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/modpathol.2013.173","article-title":"Gastrointestinal stromal tumors: what do we know now?","volume":"27","author":"Corless","year":"2014","journal-title":"Mod Pathol"},{"issue":"9896","key":"10.1016\/j.ejca.2017.02.007_bib2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.007_bib3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.007_bib4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2017.02.007_bib5","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in\u00a0vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1078\u20130432","key":"10.1016\/j.ejca.2017.02.007_bib6","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2017.02.007_bib7","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s00280-010-1513-8","article-title":"Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor","volume":"67","author":"Wang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.007_bib8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.humpath.2013.10.025","article-title":"High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors","volume":"45","author":"K\u00fcnstlinger","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.007_bib9","doi-asserted-by":"publisher","first-page":"iii21","DOI":"10.1093\/annonc\/mdu255","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"The ESMO\/European Sarcoma Network Working Group","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2017.02.007_bib10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","article-title":"NCCN task force report: update on the management of patients with gastrointestinal stromal tumors","volume":"8","author":"Demetri","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.007_bib11","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2214\/ajr.183.6.01831619","article-title":"CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings","volume":"183","author":"Choi","year":"2004","journal-title":"AJR Am J Roentgenol"},{"issue":"13","key":"10.1016\/j.ejca.2017.02.007_bib12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2017.02.007_bib13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors","volume":"13","author":"Choi","year":"2008","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.ejca.2017.02.007_bib14","doi-asserted-by":"crossref","first-page":"30242","DOI":"10.18632\/oncotarget.7148","article-title":"Intratumoral KIT mutational heterogeneity and recurrent KIT\/PDGFRA mutations in KIT\/PDGFRA wild-type gastrointestinal stromal tumors","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.007_bib15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2014.57.4970","article-title":"KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence","volume":"33","author":"Joensuu","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.007_bib16","first-page":"41","volume":"vol. 33 (8)","author":"Fanta","year":"2015"},{"key":"10.1016\/j.ejca.2017.02.007_bib17","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Heinrich","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.007_bib18","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1053\/j.gastro.2006.09.017","article-title":"Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity","volume":"131","author":"Weisberg","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.007_bib19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","article-title":"Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants","volume":"128","author":"Debiec-Rychter","year":"2005","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.ejca.2017.02.007_bib20","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","article-title":"Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation","volume":"14","author":"Dewaele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.007_bib21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/1078-0432.CCR-06-1508","article-title":"Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors","volume":"13","author":"Agaram","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.007_bib22","first-page":"6617","article-title":"Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment\u2013lessons learned","volume":"34","author":"Cheng","year":"2014","journal-title":"Anticancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T09:44:26Z","timestamp":1568886266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":22,"alternative-id":["S0959804917307323"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour\u00a0patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}